Guidelines for Providers of Chelation Therapy

The immense and precious value of chelation therapy is increasingly being recognized by thousands of people all over the world. With its gain of fame also comes an understanding of the accompanying responsibility and pertinent guidelines for carrying out the practice. There are several resources and providers for chelation therapy which need to be recognized by therapists. Due to its peculiar nature of therapy several guidelines have been formulated for recommending chelation therapy which are absolutely essential to instill a sense of confidence among the patients.

Several reports, called Progressive Correct Action (PCA) reports, were developed by the centers for medical services to conduct meaningful chelation therapy review. Through sampled therapy reports they seek out errors and educate providers concerning those errors. The major finding that was deduced by using such reports is the complete absence of relevant documentation. These reports also search out validation for using EDTA agents to treat patients.

Such reports also provide useful tips to both providers, as to how chelation therapy is to be provided to patients under a set of specified conditions, and to patients, allowing them to make informed decisions. However, a therapy provider must know some of the most important advisories while practicing chelation therapy.

1. Probably you will be surprised to know that chelation therapy for arteriosclerosis is not at all covered by Medicare insurance claims. This information must be shared with the patient who is wishing to undergo chelation therapy.

2. Providers must also inform their patients that all sundry services connected with non-covered services are not covered by Medicare. Thus chelation therapy related services like lab tests, infusions and other associated services are not covered under Medicaid.

3. The decision to conduct a chelation therapy session must be based on a complete analysis of patient's condition and previous history.

4. Treating patients with sensitive renal and neural abnormalities is not recommended as the effect of chelation is not yet confirmed in such cases.

5. Before administering chelation therapy, blood tests must be conducted to find out the toxicity levels.

6. Chelation therapy can sometimes create severe side effects. Treating patients for illness must be based on sound judgment, evidence and a good standard of practice.

7. When a patient is screened for metal toxicity it is not considered for Medicare benefit.

8. Though quantifying the excretion of heavy metals in the urine immediately after chelation may provide a positive result, this must be only treated as previous exposure not current poisoning.